<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8079">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707004</url>
  </required_header>
  <id_info>
    <org_study_id>HO11421</org_study_id>
    <nct_id>NCT01707004</nct_id>
  </id_info>
  <brief_title>Decitabine Followed by Partially Matched Related Bone Marrow Transplant for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Decitabine Followed by Partially Matched Related Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the results of chemotherapy and radiation given before
      and after a bone marrow transplant from a partially mismatched related donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase II study of decitabine followed by myeloablative conditioning,
      transplantation of partially HLA-mismatched bone marrow and post-transplantation
      cyclophosphamide in patients with acute myelogenous leukemia, and high-risk myelodysplastic
      syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary objective is to determine overall survival at 100 days after transplantation following decitabine and a HLA-haploidentical bone marrow transplantation using a myeloablative preparative regimen and post-transplantation cyclophosphamide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil recovery</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: neutrophil recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of graft failure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asessment of Acute GVHD and Chronic GVHD</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Acute graft-versus-host disease (GVHD)and chronic GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Incidence of infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Treatment-related mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet recovery</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: platelet recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse/progression</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Time to relapse/progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients enrolled in this study will also be followed for the following endpoints: Progression-free survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive decitabine 20 mg/m2 IV for 10 consecutive days.  Beginning 7 - 14 days later, patients will receive 12 Gy total body radiation followed by bone marrow transplant.  GVHD prophylaxis will consist of high dose cyclophosphamide, mycophenolate mofetil, and tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow transplant</intervention_name>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>12 Gy Total body radiation</intervention_name>
    <arm_group_label>Decitabine, bone marrow transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myelogenous leukemia

          -  Myelodysplastic syndromes

          -  Available related donor that is at least a high resolution (allele level) haplotype
             match at HLA A, B, C, DRB1 and DQB1.

        Exclusion Criteria:

          -  Active CNS leukemia within two weeks of registration

          -  New or active infection

          -  Active HIV, hepatitis A, B or C infection

          -  Allergy or hypersensitivity to agents used within the treatment protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark B Juckett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark B Juckett, M.D.</last_name>
    <phone>608-263-0338</phone>
    <email>mbj@medicine.wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark B Juckett, M.D.</last_name>
      <phone>608-263-0338</phone>
      <email>mbj@medicine.wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
